Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle Sells 2,320 Shares

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 2,320 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total value of $42,734.40. Following the completion of the transaction, the chief financial officer now owns 259,959 shares of the company’s stock, valued at $4,788,444.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

David Mountcastle also recently made the following trade(s):

• On Tuesday, April 2nd, David Mountcastle sold 3,933 shares of Privia Health Group stock. The shares were sold at an average price of $17.77, for a total value of $69,889.41.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA traded up $0.38 during midday trading on Thursday, hitting $18.41. 782,205 shares of the stock traded hands, compared to its average volume of 940,409. The company has a market cap of $2.18 billion, a PE ratio of 96.90, a P/E/G ratio of 2.51 and a beta of 0.81. Privia Health Group, Inc. has a one year low of $17.54 and a one year high of $30.15. The business has a 50 day moving average price of $19.67 and a two-hundred day moving average price of $21.16.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The company had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. During the same quarter last year, the company posted $0.14 EPS. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. As a group, equities research analysts forecast that Privia Health Group, Inc. will post 0.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently bought and sold shares of the stock. Covestor Ltd boosted its position in Privia Health Group by 8.3% in the third quarter. Covestor Ltd now owns 6,703 shares of the company’s stock worth $154,000 after purchasing an additional 514 shares during the last quarter. Yousif Capital Management LLC boosted its position in Privia Health Group by 1.1% in the fourth quarter. Yousif Capital Management LLC now owns 52,628 shares of the company’s stock worth $1,212,000 after purchasing an additional 563 shares during the last quarter. New York State Common Retirement Fund boosted its position in Privia Health Group by 2.7% in the third quarter. New York State Common Retirement Fund now owns 27,966 shares of the company’s stock worth $643,000 after purchasing an additional 737 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Privia Health Group by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,970 shares of the company’s stock worth $176,000 after purchasing an additional 756 shares during the last quarter. Finally, Glenmede Trust Co. NA boosted its position in Privia Health Group by 0.9% in the third quarter. Glenmede Trust Co. NA now owns 107,711 shares of the company’s stock worth $2,477,000 after purchasing an additional 976 shares during the last quarter. Institutional investors own 94.48% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on PRVA shares. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a report on Tuesday, March 19th. JPMorgan Chase & Co. reduced their price objective on shares of Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 6th. UBS Group lowered their price objective on Privia Health Group from $31.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Citigroup started coverage on Privia Health Group in a research note on Monday, April 22nd. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Bank of America lowered Privia Health Group from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $27.00 to $21.00 in a research note on Thursday, February 22nd. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.62.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.